Improved Service Efficiency Improves Racial Disparity in Diabetic Care

Abel Irena  
Kushal Patel  
David Thompson  
Gregory Schleis  
Abiy Gesese  
Richard Battiola

Follow this and additional works at: https://aurora.org/jpcrr

Part of the Clinical Epidemiology Commons, Endocrinology, Diabetes, and Metabolism Commons, Health Services Research Commons, Internal Medicine Commons, and the Nutritional and Metabolic Diseases Commons

Recommended Citation


Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience.
Conclusion: Within Aurora, metabolic syndrome is rarely and variably diagnosed in medical practice, despite clear evidence of satisfied ATP III and WHO criteria.

Improved Service Efficiency Improves Racial Disparity in Diabetic Care

Abel Irena, Kushal Patel, David Thompson, Gregory Schleis, Abiy Gesese, Richard Battiola
Department of Internal Medicine, Aurora Sinai Medical Center; Aurora University of Wisconsin Medical Group

Background: Racial disparities in diabetes care have been documented. Disparities also have been shown to affect service quality and outcome of diabetic care. Analysis of our internal medicine residency clinic diabetic care management performance across REAL-G (race, ethnicity, age, preferred language and/or gender) showed race-based disparity on two outcome measures: 1) measurement of glycohemoglobin (A1C) at least twice a year; and 2) target blood pressure of < 140/90.

Purpose: Develop interventions to decrease racial disparities in diabetes care among patients managed by an internal medicine residency clinic, as part of the Alliance of Independent Academic Medical Center’s National Initiative V project.

Methods: Interventions were developed following analysis of clinical performance data by REAL-G categories, workflow analysis and multidisciplinary clinic team meetings. A point-of-care A1C machine was procured and workflow developed using the Plan-Do-Study-Act cycle. Staff training was conducted. A rolling 12 months data set was obtained from electronic health records. Baseline data range was December 2014 to November 2015, while endline data were from January 2016 to December 2016. The interventions were launched in July 2016. Percentage difference between baseline and endline outcome indicators was calculated and Z-score test assessed. Statistical significance was set at P<0.05.

Results: At baseline, 62.9% (401 of 638) of patients who self-identified as African American/black (AA) had A1C measured at least twice a year compared to 74.3% (107 of 144) of patients who self-identified as white/Caucasian (WC), a percentage difference of 11.4% (P=0.01). For goal blood pressure in diabetics, 71.0% (453 of 638) identified as white/Caucasian (WC), a percentage difference of 11.4% (P=0.01). For goal blood pressure in diabetics, 71.0% (453 of 638) identified as white/Caucasian (WC), a percentage difference of 11.4% (P=0.01).

Conclusion: Within Aurora, metabolic syndrome is rarely and variably diagnosed in medical practice, despite clear evidence of satisfied ATP III and WHO criteria.

Aurora Research Institute; Aurora Neuroscience Innovation Institute

Background: The incidence of brain metastasis appears to be increasing, potentially due to advanced technology that aids early diagnosis. Patient-derived xenografts (PDX) have high translational value, as these models retain key functional characteristics of the patient tumor. PDX models are useful to understand the molecular basis of tumorigenesis and to identify new treatment targets. However, generating a first-line PDX model is challenging as engraftment failure is high. Serial transplanting tumor tissue via mouse-to-mouse propagation increases engraftment rates and decreases PDX development time. Herein we report methods to generate a PDX cell line from patient-derived tumor tissue that includes the cerebral aqueduct as a novel intracranial orthotopic implantation site.

Purpose: Develop human tumors in mouse models for therapeutic purpose.

Methods: Patient-derived brain metastasis tumor tissue was enzymatically dissociated into a single cell suspension and maintained in neurocult media supplemented with human recombinant bFGF and EGF (20 ng/ml). The cells were seeded at a density of 1.0 × 104/cm2 on ultra-low attachment plates and maintained at 37°C with 5% CO2. PDX models were generated via orthotopic stereotactic surgeries. Athymic nude mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). The cerebral aqueduct was located using these coordinates from bregma: A: -5; L: +0.2; V: -2.4. Mice were injected with 5.0 × 104 cells in 2 μl of media at a rate of 0.4 ul/min. Mice were monitored daily for symptoms of tumor formation. Upon becoming symptomatic, mice were euthanized and tumor tissue was harvested for both culture and H&E stain for tumor verification.

Results: Mice injected with primary patient cells (first-generation mice) developed tumors at 7 weeks (average: 6.77 weeks), second-generation mice yielded tumors at 2 weeks (average: 13.5 days), and third-generation mice replicated results from second-generation mice (average: 13 days). H&E stain revealed invasive tumor masses in the ventricular system that extended from the cerebral aqueduct to the lateral ventricles. Immunohistochemistry analysis confirmed the third-generation cell line retained key characteristics of the patient tumor.

Conclusion: These methods successfully generated a PDX cell line from patient-derived brain metastasis that demonstrates reliable tumor formation and phenotypic stability. Importantly, our unique intracranial implantation site revealed several distinct masses, a hallmark of brain metastasis in patients.

Decreasing Time to Broad Spectrum Antibiotics for Septic Patients in the Emergency Department

Joseph J. Zieminski, Emily E. Bryant
Department of Pharmacy, Aurora St. Luke’s Medical Center

Background: Timely administration of broad spectrum antibiotics has been shown to be directly correlated with decreased mortality for patients with severe sepsis and septic shock. As such, both the Surviving Sepsis Campaign and the SEP-1 CMS measure recognize timely antibiotic administration as a cornerstone of therapy for patients with severe sepsis or septic shock.

Purpose: Decrease time to broad spectrum antibiotic administration for septic patients in the emergency department (ED) of Aurora St. Luke’s Medical Center.

Methods: An alert within the electronic medical record was created to more rapidly identify potentially septic patients in the ED. After